Glycopyrronium Bromide Martindale (Glycopyrronium Bromide)

Glycopyrronium Bromide Martindale is indicated for several clinical situations where reduction of secretions or antispasmodic effects are desired.

• Pre‑operative reduction of salivary and bronchial secretions to improve airway management.
• Adjunctive therapy in the treatment of peptic ulcer disease to decrease gastric acid secretion.
• Management of excessive bronchial secretions in certain respiratory conditions.
• Use as an antispasmodic agent in gastrointestinal procedures.
• Facilitation of anesthesia induction by minimizing secretions.

Side effects of glycopyrronium bromide may vary in frequency and severity. Patients should be monitored for both common and serious reactions.

Common

• Dry mouth (xerostomia).
• Blurred vision or difficulty focusing.
• Tachycardia or increased heart rate.
• Constipation or reduced gastrointestinal motility.
• Urinary retention.
• Skin flushing or warmth.

Serious

• Severe tachyarrhythmias.
• Acute angle‑closure glaucoma.
• Anaphylactic or severe allergic reactions.
• Marked hypotension.
• Respiratory distress due to bronchospasm.
• Persistent urinary retention requiring intervention.

When prescribing Glycopyrronium Bromide Martindale, clinicians should consider several precautionary measures to ensure patient safety.

• Assess cardiovascular status, especially in patients with known arrhythmias.
• Use caution in individuals with glaucoma, particularly narrow‑angle type.
• Evaluate renal and hepatic function, as impairment may affect drug clearance.
• Monitor for signs of urinary retention, especially in patients with prostatic hypertrophy.
• Avoid use in patients with known hypersensitivity to anticholinergic agents.
• Consider pregnancy status; the safety profile is not well established.
• Educate patients about potential dry mouth and advise adequate hydration.

Glycopyrronium Bromide Martindale can interact with other medications, influencing its efficacy or safety profile.

Avoid

• Concurrent use with other anticholinergic drugs (e.g., atropine, scopolamine) that may exacerbate anticholinergic toxicity.
• Combination with potent CYP450 inhibitors if metabolic pathways are identified.
• Co‑administration with drugs that prolong the QT interval, increasing arrhythmia risk.

Use with caution

• Beta‑adrenergic agonists, as additive cardiovascular effects may occur.
• Opioids, which can mask signs of urinary retention.
• Medications that lower intra‑ocular pressure, requiring monitoring for glaucoma.
• Diuretics, due to potential additive effects on electrolyte balance.